Pitcairn Co. Sells 13,049 Shares of Zoetis Inc. $ZTS

Pitcairn Co. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 42.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 17,346 shares of the company’s stock after selling 13,049 shares during the period. Pitcairn Co.’s holdings in Zoetis were worth $2,538,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Norges Bank acquired a new stake in Zoetis during the 2nd quarter valued at $809,491,000. Diamond Hill Capital Management Inc. bought a new stake in shares of Zoetis during the third quarter worth $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after buying an additional 1,191,840 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its position in Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after buying an additional 922,589 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on ZTS. HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. BTIG Research reissued a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. Finally, William Blair restated an “outperform” rating on shares of Zoetis in a research report on Monday. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Performance

Shares of Zoetis stock opened at $122.06 on Friday. The firm has a fifty day moving average of $126.16 and a two-hundred day moving average of $133.42. The stock has a market capitalization of $51.53 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 1.92 and a beta of 0.95. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the company earned $1.40 EPS. The firm’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.